{"id":928138,"date":"2026-01-16T08:43:04","date_gmt":"2026-01-16T13:43:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/strive-announces-the-completion-of-semler-scientific-acquisition\/"},"modified":"2026-01-16T08:43:04","modified_gmt":"2026-01-16T13:43:04","slug":"strive-announces-the-completion-of-semler-scientific-acquisition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/strive-announces-the-completion-of-semler-scientific-acquisition\/","title":{"rendered":"Strive Announces the Completion of Semler Scientific Acquisition"},"content":{"rendered":"
\n

DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) — Strive, Inc. (Nasdaq: ASST) (\u201cStrive\u201d) today announced the successful completion of the previously announced acquisition of Semler Scientific.<\/p>\n

Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally.<\/p>\n

Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy\u2019s initial focus will be on Strive\u2019s intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.\u00a0<\/p>\n

Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Bain Capital, where he focused on biotech companies developing breakthrough therapies for underserved diseases. He later served as President and CEO of the National Institute for Health Care Management and worked as an institutional investor at J.P. Morgan, concentrating on biotechnology and healthcare. He also serves as a Senior Fellow at the Bitcoin Policy Institute and is a co-author of The Satoshi Papers, contributing thought leadership at the intersection of Bitcoin and public policy. Mr. Roy was previously an independent board member of Strive and will step down from that position to join the company in a full-time capacity and serve as a board observer for the company.<\/p>\n

Eric Semler, former chairman and Executive Chairman of Semler Scientific, has joined as an independent board member of Strive.<\/p>\n

Joe Burnett, previously director of Bitcoin Strategy for Semler Scientific, has joined Strive as VP of Bitcoin Strategy.<\/p>\n

\n About Strive<\/b>\n <\/p>\n

Strive is the first publicly traded asset management Bitcoin treasury company. Strive is focused on increasing Bitcoin per share to outperform Bitcoin over the long run. Strive holds approximately 12,797.9 bitcoins as of January 16, 2025.<\/p>\n

Since launching its first ETF in\u00a0August 2022,\u00a0Strive Asset Management, LLC, a direct, wholly owned subsidiary of Strive and an\u00a0SEC-registered investment adviser, has grown to manage over\u00a0$2 billion\u00a0in assets.<\/p>\n

\n About Semler Scientific, Inc. (Nasdaq: SMLR)<\/b>
\n
Semler Scientific, Inc. is the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and is a leader in medical devices and software to combat chronic diseases. In addition, through its healthcare businesses, Semler Scientific and its wholly-owned subsidiary, CardioVanta, Inc. develop and market products and services for early detection and monitoring of chronic diseases. Semler Scientific’s flagship product, QuantaFlo, which is patented and cleared by the U.S. Food and Drug Administration (FDA), provides rapid point-of-care testing to measure arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of peripheral arterial disease. Additional information about Semler Scientific can be found at www.semlerscientific.com<\/a>.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements<\/b>\n <\/p>\n

Certain statements in this press release may constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), and Rule\u00a03b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Strive and Semler Scientific, Inc. (\u201cSemler Scientific\u201d), respectively, with respect to the proposed transaction (the \u201cproposed transaction\u201d), the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company\u2019s future financial performance, the timing of the closing of the proposed transaction, the ability to successfully integrate the combined businesses, the size and timing of the offering, the anticipated use of any proceeds from the offering, the terms of the securities being offered and the Company\u2019s intentions with respect to adjusting the SATA Stock monthly regular dividend rate per annum. Such statements are often characterized by the use of qualified words (and their derivatives) such as \u201cmay,\u201d \u201cwill,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cassume,\u201d \u201cforecast,\u201d \u201ctarget,\u201d \u201cbudget,\u201d \u201coutlook,\u201d \u201ctrend,\u201d \u201cguidance,\u201d \u201cobjective,\u201d \u201cgoal,\u201d \u201cstrategy,\u201d \u201copportunity,\u201d and \u201cintend,\u201d as well as words of similar meaning or other statements concerning opinions or judgment of Strive, Semler Scientific or their respective management about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all. Other risks, uncertainties and assumptions, including, among others, the following:<\/p>\n